Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Fluticasone furoate/Umeclidinium/Vilanterol (Trelegy®)

Brand: Trelegy®
Indication: Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.
Disease category: Respiratory system
Commissioning responsibility: CCG
PbR excluded: No


Trelegy Ellipta® inhalation powder is recommended as an option for the treatment of COPD with the following restriction:

Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.


LMMG recommendation: Green (Restricted)
Click here to find the definitions for the colour classifications

Reason for decision:  Suitable for initiation in primary care (in line with restrictions)

Supporting documents:

New Medicine Recommendation - Trelegy Ellipta (286.6 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG


Green (Restricted)

Green (Restricted)

Green (restricted)

Green (Restricted)

Green (Restricted)